Skip to main content
Chinese Journal of Hepatology logoLink to Chinese Journal of Hepatology
. 2017 Jun 20;25(6):419–423. [Article in Chinese] doi: 10.3760/cma.j.issn.1007-3418.2017.06.006

乙型肝炎病毒和丙型肝炎病毒慢性感染者肝组织病理学炎症及纤维化对比分析

The comparison of liver inflammation and fibrosis between chronic HBV and HCV infection

Wang Lin 1, Fan Yaoxin 1, Ding Yang 1, Sheng Qiuju 1, Zhang Chong 1, Zhao Lianrong 1, Xia Tingting 1, An Ziying 1, Bai Han 1, Shi Haiyuan 1, Dou Xiaoguang 1,通信作者:
Editor: 孙 宇航
PMCID: PMC12677367  PMID: 28763858

Abstract

Objective

To explore the difference of liver inflammation and fibrosis in patients with chronic hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV) infection, and to investigate the relationship between hepatic pathology and alanine aminotransferase (ALT).

Methods

57 patients with chronic HCV infection and 346 patients with chronic HBV infection who were hospitalized at Shengjing Hospital of China Medical University from January 2012 to September 2016 were enrolled. In chronic HBV infection, including 88 cases whose ALT were more than two times of upper limited of normal (ALT≥2×ULN)and 258 cases whose ALT were less than two times of upper limited of normal (ALT<2×ULN). All the patients were underwent liver biopsy. Chronic HBV infection (ALT≥2×ULN and ALT<2×ULN) and chronic HCV infection were compared respectively. Statistical analyses were performed using a Univariate X2-test and Mann-Whitney U test for comparison. Correlations between variables were analyzed using Spearman's rank correlation.

Results

In chronic HBV infection group, 169 cases (48.8%) had inflammation grade≥2 (G≥2), 98 cases (28.3%) had fibrosis stage≥2 (S≥2), 81 cases (23.4%) with G≥2 and S≥2. In the ALT<2×ULN group, there were 109 cases (42.2%) with G≥2, 62 cases (24%) with S≥2, 49 cases (19%) with G≥2 and S≥2. In the ALT≥2×ULN group, 60 cases (68.2%) with G≥2, 35 cases (39.8%) with S≥2, 31 cases (35.2%) with G≥2 and S≥2. The grade of inflammation and fibrosis have significantly different between ALT≥2×ULN group and ALT<2×ULN group (X2=17.66, X2=8.06, P<0.01). In chronic HCV infection group, 47 cases (82.5%) with G≥2, 20 cases (35.1%) with S≥2, 20 cases (35.1%) with G≥2 and S≥2. ALT had no correlation with inflammation and fibrosis (P>0.05). The grade of inflammation was significantly different between chronic HCV infection and chronic HBV infection whose ALT<2×ULN (X2=30.19, P<0.01) but the fibrosis have no difference (X2=2.96, P>0.05). Compared with chronic HBV infection whose ALT≥2×ULN, both inflammation and fibrosis had no significantly different (X2=3.65,X2=0.32, P>0.05 respectively).

Conclusion

In chronic HBV infection whose ALT<2×ULN, about 30%-40% liver tissue with significant necroinflammation and /or fibrosis. About 80% chronic HCV infection with significant necroinflammation, and the grade of inflammation has no correlation with ALT. The grade of inflammation has significantly different between chronic HCV infection group and chronic HBV infection group whose ALT<2×ULN.

Keywords: Hepatitis B virus, Hepatitis C virus, Pathology, Inflammation, Fibrosis


乙型肝炎病毒(hepatitis B virus,HBV)和丙型肝炎病毒(hepatitis C virus,HCV)感染后容易导致肝组织发生炎症和(或)纤维化。指南推荐:当肝组织炎症和(或)纤维化程度≥2级时应当立即进行抗病毒治疗;当炎症和(或)纤维化<2级时要根据病毒载量、血清丙氨酸氨基转移酶(alanine aminotransferase,ALT)水平和肝脏疾病严重程度来决定是否进行抗病毒治疗[123]。在临床治疗过程中我们发现慢性乙型肝炎(chronic hepatitis B,CHB)与慢性丙型肝炎(chronic hepatitis C,CHC)患者抗病毒治疗效果是不同的,尤其是ALT处于正常或轻度异常的HBV慢性感染者往往抗病毒治疗效果不佳,HCV慢性感染者无论ALT水平高低,抗病毒疗效均无明显差别。因此,本研究通过对慢性HBV和HCV感染者进行肝组织病理学检查,以期探讨两者肝组织病理炎症和纤维化的不同特点及与ALT的关系。

资料与方法

1.研究对象:收集2012至2016年在中国医科大学附属盛京医院住院的行肝组织活检的HBV慢性感染者346例[包括ALT≥2×正常值上限(ULN)88例和ALT<2×ULN 258例]和HCV慢性感染者57例。入选标准:符合我国2015年《慢性乙型肝炎防治指南》和《丙型肝炎防治指南》,所有患者均未进行抗病毒治疗,除外合并其他肝脏疾病。

2.病理学检查:本次研究的患者均接受经皮肝穿刺活组织检查,所取组织长度至少1 cm以上,包含5个或者以上完整的汇管区,标本用甲醛溶液固定,石蜡包埋,常规使用苏木素伊红染色。所有活组织检查样本被2名有经验的病理医师审核诊断。病理医师对患者生物化学以及病毒学检测结果均不了解。使用Scheuer评分系统评价肝组织炎症分级和纤维化分期情况。肝组织炎症活动度等级为:(1)G0:肝组织汇管区及其周围无炎症,同时肝小叶内亦无炎症;(2)G1:汇管区炎症,小叶内可见肝细胞变性及少数点、灶状坏死灶;(3)G2:汇管区及周围轻度碎屑状坏死,小叶内变性,点、灶状坏死或嗜酸性小体;(4)G3:汇管区及周围中度碎屑状坏死,小叶内可见变性,融合坏死或见桥接坏死;(5)G4:汇管区及周围重度碎屑状坏死,桥接坏死范围广,多小叶坏死。肝脏纤维化分期为:(1)S0:无纤维化;(2)S1:汇管区无纤维化扩大,局限窦周及小叶内纤维化;(3)S2:汇管区周围纤维化,纤维间隔形成,小叶结构保留;(4)S3:纤维间隔及小叶结构紊乱,但无肝硬化;(5)S4:早期肝硬化。肝组织炎症活动度G≥2时,提示肝组织存在着明显的坏死性炎症;肝脏纤维化分期S≥2时,提示肝组织存在着明显的纤维化。

3.病毒血清学检测:使用化学发光微粒子免疫法(雅培i2000全自动化学发光免疫分析仪,美国)检测HBs Ag、抗-HBs、HBe Ag、抗-HBe、抗-HBc和抗-HBc-免疫球蛋白M)及丙型肝炎抗体。

4.统计学方法:用SPSS22.0统计学软件进行数据分析处理。所有计量资料均采用均数±标准差(graphic file with name cjh-25-06-419-F901c.jpg±s)表示。计数资料采用x2检验,非正态分布数据采用Mann-Whitney U检验,相关性分析采用Spearman等级相关性分析。所有检验均为双侧检验,P<0.05表示差异有统计学意义。

结果

1.一般情况:共346例慢性HBV感染者(包括ALT≥2×ULN 88例和ALT<2×ULN 258例)和57例慢性HCV感染者符合入选标准。在346例慢性HBV感染者中,男性占202例(58.4%),平均年龄(37.36±10.17)岁,ALT(74.12±94.74)U/L;在57例慢性HCV感染者中,男性占35例(61.4%),平均年龄(46.49±11.84)岁,ALT(80.84±79.23)U/L。

2.慢性HBV感染者和慢性HCV感染者肝组织炎症活动度和纤维化分期比较:346例慢性HBV感染者中,肝组织炎症活动度G≥2级169例(48.8%),纤维化S≥2期98例(28.3%),G≥2级且S≥2期共81例(23.4%),无或轻度肝组织损伤(G<2级且S<2期)有160例(46.2%);57例慢性HCV感染者中,G≥2级47例(82.5%),S≥2期20例(35.1%),G≥2级且S≥2期共20例(35.1%),无或轻度肝组织损伤(G<2级且S<2期)有10例(17.5%)。慢性HCV感染者肝组织损伤发生率高于慢性HBV感染者(x2=16.53,P<0.01),见表1

表1. 乙型肝炎病毒和丙型肝炎病毒慢性感染者肝组织炎症活动度和纤维化分期的分布[例(%)].

组别 肝组织炎症活动度 G 2 肝组织纤维化分期 S 2 炎症伴有纤维化 G 2 S 2
乙型肝炎病毒慢性感染组(n=346) 169(48.8) 98(28.3) 81(23.4)
丙型肝炎病毒慢性感染组(n=57) 47(82.5) 20(35.1) 20(35.1)

3.不同ALT水平的慢性HBV感染者肝组织炎症活动度和纤维化分期比较:在ALT<2×ULN的慢性HBV感染者中,G≥2级109例(42.2%),S≥2期62例(24%),G≥2级且S≥2期共49例(19%);在ALT≥2×ULN的慢性HBV感染者中,G≥2级60例(68.2%),S≥2期35例(39.8%),G≥2级且S≥2期共31例(35.2%)。ALT≥2×ULN的慢性HBV感染者的肝组织炎症坏死程度及纤维化程度明显高于ALT<2×ULN组(x2=17.66,x2=8.06,P值均<0.01),见表2

表2. 不同丙氨酸氨基转移酶水平的乙型肝炎病毒慢性感染者肝组织炎症活动度和纤维化分期的分布[例(%)].

组别 肝组织炎症活动度 G 2 肝组织纤维化分期 S 2 炎症伴有纤维化 G 2 S 2
丙氨酸氨基转移酶≥2×正常值上限(n=88) 60(68.2) 35(39.8) 31(35.2)
丙氨酸氨基转移酶<2×正常值上限(n=258) 109(42.2) 62(24) 49(19.0)

4.不同ALT水平的慢性HBV感染者和慢性HCV感染者肝组织炎症活动度和纤维化分期比较:慢性HCV感染者肝组织炎症坏死程度明显高于ALT<2×ULN的慢性HBV感染者(x2=30.19,P<0.01),而纤维化程度在两组间差异无统计学意义(x2=2.96,P>0.05)。慢性HCV感染者与ALT≥2×ULN的慢性HBV感染者相比,在肝组织炎症坏死程度和纤维化程度上差异均无统计学意义(x2=3.65,x2=0.32,P值均>0.05)。

5.ALT水平与肝组织病理改变:ALT水平与慢性HBV感染者肝组织炎症及纤维化程度有相关性(r=0.302,r=0.205,P值均<0.0i,);ALT水平与慢性HCV感染者肝组织炎症及纤维化程度均无相关性(P值均>0.05)。

讨论

慢性乙型肝炎和慢性丙型肝炎是呈世界性流行的传染病。据世界卫生组织统计,全球约有20亿人曾感染HBV,其中2.4亿人为慢性HBV感染者[4],约1.85亿人为HCV感染[5]。目前认为HBV和HCV感染后,导致肝组织损伤的主要原因是机体免疫系统造成的损伤。肝细胞变性坏死,同时伴有不同程度的炎症细胞浸润是病毒性肝炎的主要病理表现。肝细胞损伤和炎症反应是肝纤维化的始动环节[6]。慢性炎症过程中所释放的炎性因子,刺激肝星状细胞活化,继而分泌大量的细胞外基质,导致肝纤维化的发生[78910]。虽然两者具有相似的病理改变,但是在临床治疗效果上却存在很大的差异。我们推测其肝组织病理改变程度是导致这种差异的重要原因。

本研究首先分析了346例慢性HBV感染者和57例慢性HCV感染者的肝组织病理检查结果。在慢性HBV感染者中,肝组织炎症活动度G≥2级占48.8%,纤维化S≥2期占28.3%,无或轻度肝组织损伤占46.2%;慢性HCV感染者中,G≥2级占82.5%,S≥2期占35.1%,无或轻度肝组织损伤仅占17.5%。通过比较发现慢性HCV感染者肝组织炎症坏死程度明显高于慢性HBV感染者炎症坏死程度;慢性HCV感染者肝组织纤维化发生率高于慢性HBV感染者,但差异无统计学意义。不仅慢性HCV感染出现肝组织损伤明显高于慢性HBV感染,并且大部分的慢性HCV感染者肝组织存在着明显炎症。我们推测导致这种差异的原因可能与以下因素有关:首先,HCV病毒自身具有直接导致肝组织损伤的作用,HCV可以通过增加溶酶体膜的通透性、表达毒性蛋白等引起损伤,与HCV截然相反的是HBV病毒本身并不直接导致肝细胞损伤。其次,在HCV引起的免疫应答中,细胞毒性T淋巴细胞起着重要作用[11]。细胞毒性T淋巴细胞在杀伤病毒的同时也造成了肝细胞的损伤。在慢性HBV感染中,HBV特异性T淋巴细胞容易发生凋亡,并且分泌细胞因子功能和增殖能力是明显下降的,T淋巴细胞功能耗竭[12]。本实验结果也证明慢性HCV感染者的肝组织炎症程度重于慢性HBV感染,这也从侧面解释了两者在抗病毒治疗效果中存在差异的原因。

我们进一步对慢性HBV感染者的ALT≥2×ULN组、ALT<2×ULN组和慢性HCV感染者分别进行肝组织病理比较。结果显示ALT≥2×ULN的慢性HBV感染者肝组织炎症坏死及纤维化程度明显高于ALT<2×ULN的慢性HBV感染者。慢性HCV感染者肝组织炎症坏死程度明显高于ALT<2×ULN的慢性HBV感染者,并且差异有统计学意义;虽然慢性HCV感染者肝组织纤维化程度也高于ALT<2×ULN的慢性HBV感染者,但差异无统计学意义。慢性HCV感染者与ALT≥2×ULN的慢性HBV感染者相比,无论肝组织炎症坏死程度还是纤维化严重程度差异均无统计学意义。综上所述,慢性HCV感染者、ALT≥2×ULN的慢性HBV感染者的肝组织炎症坏死程度明显重于ALT<2×ULN的慢性HBV感染者。在临床治疗中,慢性HCV感染者、ALT≥2×ULN的慢性HBV感染者抗病毒治疗效果往往优于ALT<2×ULN的慢性HBV感染者,我们推测肝组织炎症程度在很大程度上影响着抗病毒治疗效果。

ALT是临床上常用的反映肝组织炎症的血清学指标。我国最新的指南指出对于ALT≥2×ULN的慢性HBV感染者应及时抗病毒治疗。对ALT<2×ULN的慢性HBV感染者,存在明显的肝脏炎症(2级以上)或纤维化,特别是肝纤维化2级以上的患者应进行抗病毒治疗[13]。所有HCV RNA阳性的患者,无治疗禁忌证均应该接受抗病毒治疗[14]。在本研究中,慢性HBV感染者的ALT水平与肝组织炎症及纤维化有相关性。此外,在ALT<2×ULN组,肝组织出现明显坏死性炎症的有109例,明显纤维化的有62例,G≥2级且S≥2期共49例。这说明即使在ALT<2×ULN的慢性HBV感染者中,仍有相当一部分患者存在着明显的肝组织炎症和(或)纤维化,ALT水平与肝组织炎症活动度并不完全平行,这也与之前的报道相一致[15161718]。然而,与慢性HBV感染不同的是慢性HCV感染者的ALT水平与肝脏炎症及纤维化程度无关。因此,ALT水平不能作为反映慢性HCV感染者肝组织炎症活动的指标。

利益冲突

作者贡献声明

王琳、樊耀昕:实验设计、数据分析、撰写论文;丁洋、盛秋菊、张翀、赵连荣、夏婷婷、安子英、白菡:病例收集;石海源:病例收集、采集数据;窦晓光:提出研究思路,审阅、修改论文

参考文献

  • [1].European Association for the Study of the Liver . EASL recommendations on treatment of hepatitis C 2016[J]. J Hepatol, 2017,66(1):153-194. DOI: 10.1016/j.jhep.2016.09.001. [DOI] [PubMed] [Google Scholar]
  • [2].Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection-EASL Special Conference[J]. J Hepatol, 2015,63(5):1238-1253. DOI: 10.1016/j.jhep.2015.06.026. [DOI] [PubMed] [Google Scholar]
  • [3].Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016,63(1):261-283. DOI: 10.1002/hep.28156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4].Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine, 2012,30(12):2212-2219. DOI: 10.1016/j.vaccine.2011.12.116. [DOI] [PubMed] [Google Scholar]
  • [5].Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology, 2013,57(4):1333-1342. DOI: 10.1002/hep.26141. [DOI] [PubMed] [Google Scholar]
  • [6].Pradere JP, Kluwe J, De Minicis S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice[J]. Hepatology, 2013,58(4):1461-1473. DOI: 10.1002/hep.26429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Marra F, Tacke F. Roles for chemokines in liver disease[J]. Gastroenterology, 2014,147(3):577-594.e1. DOI: 10.1053/j.gastro.2014.06.043. [DOI] [PubMed] [Google Scholar]
  • [8].Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells[J]. Semin Liver Dis, 2001,21(3):373-384. DOI: 10.1055/s-2001-17552. [DOI] [PubMed] [Google Scholar]
  • [9].Bi Y, Mukhopadhyay D, Drinane M, et al. Endocytosis of collagen by hepatic stellate cells regulates extracellular matrix dynamics[J]. Am J Physiol Cell Physiol, 2014,307(7):C622-633. DOI: 10.1152/ajpcell.00086.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Tacke F, Weiskirchen R. Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques[J]. Expert Rev Gastroenterol Hepatol, 2012,6(1):67-80. DOI: 10.1586/egh.11.92. [DOI] [PubMed] [Google Scholar]
  • [11].Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J]. World J Gastroenterol, 2013,19(44):7896-7909. DOI: 10.3748/wjg.v19.i44.7896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J]. Gut, 2012,61(12):1754-1764. DOI: 10.1136/gutjnl-2011-301073. [DOI] [PubMed] [Google Scholar]
  • [13].中华医学会肝病学分会,中华医学会感染病学分会 . 慢性乙型肝炎防治指南(2015更新版)[J]. 中华肝脏病杂志, 2015,23(12):888-905. DOI: 10.3760/cma.j.issn.1007-3418.2015.12.002. [DOI] [Google Scholar]; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Disease, Chinese Medical Association . The guideline for prevention and treatment of chronic hepatitis B (2015)[J]. Chin J Hepatol, 2015,23(12):888-905. DOI: 10.3760/cma.j.issn.1007-3418.2015.12.002. [DOI] [Google Scholar]
  • [14].中华医学会肝病学分会,中华医学会感染病学分会 . 丙型肝炎防治指南(2015更新版)[J]. 中华肝脏病杂志, 2015,23(12):906-923. DOI: 10.3760/cma.j.issn.1007-3418.2015.12.003. [DOI] [Google Scholar]; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Disease, Chinese Medical Association . Guideline for prevention and treatment of chronic hepatitis C (2015)[J]. Chin J Hepatol, 2015,23(12):906-923. DOI: 10.3760/cma.j.issn.1007-3418.2015.12.003. [DOI] [Google Scholar]
  • [15].Zheng X, Wang J, Yang D. Antiviral therapy for chronic hepatitis B in China[J]. Med Microbiol Immunol, 2015,204(1):115-120. DOI: 10.1007/s00430-014-0380-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Gui HL, Wang H, Yang YH, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase[J]. J Viral Hepat, 2010,17 Suppl 1:44-50. DOI: 10.1111/j.1365-2893.2010.01270.x. [DOI] [PubMed] [Google Scholar]
  • [17].Nguyen MH, Garcia RT, Trinh HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels[J]. Am J Gastroenterol, 2009,104(9):2206-2213. DOI: 10.1038/ajg.2009.248. [DOI] [PubMed] [Google Scholar]
  • [18].Alam S, Ahmad N, Mustafa G, et al. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B[J]. Liver Int, 2011,31(6):824-830. DOI: 10.1111/j.1478-3231.2011.02491.x. [DOI] [PubMed] [Google Scholar]

Articles from Chinese Journal of Hepatology are provided here courtesy of Second Affiliated Hospital of Chongqing Medical University

RESOURCES